(Reuters) – India’s drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science’s experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday.
The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said.
India’s Cipla Ltd (NS:) has also received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug, according to a report https:// in Indian Express.
Cipla and DGCI were not immediately available for comment.
Gilead Sciences Inc (O:) signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its COVID-19 treatment.
The pacts allow Jubilant Life Sciences Ltd (NS:), Cipla, Hetero Labs, Mylan NV (O:) and Ferozsons Laboratories Ltd (PSX:) to make and sell the drug in 127 countries.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.